-
Anupam Rasayan Analyst Review 2027: EBITDA Up 41% as Fluorine Mix Lifts Margins
- November 19, 2026
- Posted by: Chaitanya Auti
- Category: Market
No Comments
Anupam Rasayan grew Q2 FY27 EBITDA 41% to ₹202.47 crore as margins widened to about 25%, while net profit rose 14% to ₹64.97 crore. We review brokerage views, the fluorination business, the order book, valuation and the risks for 2027.
-
3 Custom Synthesis Chemical Stocks With a Strong Future Roadmap: Aarti Industries, Anupam Rasayan India and Tatva Chintan Pharma Chem
- October 8, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Aarti Industries, Anupam Rasayan India and Tatva Chintan Pharma Chem compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.